ScholarIQanswers from OpenAlex & ORCID
Giorgio Sesti
ResearcherPublications, citations & collaboration network
Giorgio Sesti is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Giorgio Sesti have?
ScholarIQindexed works
Giorgio Sesti has 591 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Giorgio Sesti have?
ScholarIQcitation count
Giorgio Sesti has 23,279 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Giorgio Sesti?
ScholarIQh-index
Giorgio Sesti has an h-index of 78 in OpenAlex.
What is the i10-index of Giorgio Sesti?
ScholarIQi10-index
Giorgio Sesti has an i10-index of 345 in OpenAlex.
What is the ORCID of Giorgio Sesti?
ScholarIQorcid
The ORCID for Giorgio Sesti is on the source record.
What is the OpenAlex record for Giorgio Sesti?
ScholarIQopenalex
The OpenAlex for Giorgio Sesti is on the source record.
What are the most-cited papers on Giorgio Sesti?
ScholarIQmost cited works
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason Brett, Marcin Zychma, Lawrence Blonde
Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells
Massimo Federici, Rossella Menghini, Alessandro Mauriello, Marta Letizia Hribal, Francesca Ferrelli, Davide Lauro, Paolo Sbraccia, Luigi Giusto Spagnoli, Giorgio Sesti, Renato Lauro
Defects of the insulin receptor substrate (IRS) system in human metabolic disorders
Giorgio Sesti, Massimo Federici, Marta Letizia Hribal, Davide Lauro, Paolo Sbraccia, Renato Lauro
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Olga Vaccaro, Maria Masulli, Antonio Nicolucci, Enzo Bonora, Stefano Del Prato, Aldo P. Maggioni, Angela A. Rivellese, Sebastiano Squatrito, Carlo Giorda, Giorgio Sesti, Paolo Mocarelli, Giuseppe Lucisano, Michele Sacco, Stefano Signorini, Fabrizio Cappellini, G. Perriello, A.C. Babini, Annunziata Lapolla, Giovanna Gregori, Carla Giordano, L. Corsi, Raffaella Buzzetti, Gennaro Clemente, Graziano Di Cianni, R. Iannarelli, Renzo Cordera, Olga La Macchia, Chiara Zamboni, Cristiana Scaranna, Massimo Boemi, Ciro Iovine, Davide Lauro, Sergio Leotta, Elisabetta Dall’Aglio, Emanuela Cannarsa, Laura Tonutti, Giuseppe Pugliese, Antonio Bossi, Roberto Anichini, Francesco Dotta, A. Di Benedetto, Giuseppe Citro, D. Antenucci, Lucia Ricci, Francesco Giorgino, Costanza Santini, Agostino Gnasso, Salvatore De Cosmo, D. Zavaroni, Monica Vedovato, Agostino Consoli, Maria Calabrese, Paolo di Bartolo, Paolo Fornengo, Gabriele Riccardi, Olga Vaccaro, Maria Masulli, Antonio Nicolucci, Aldo P. Maggioni, Giorgio Sesti, Paolo Mocarelli, Giuseppe Lucisano, Michele Sacco, Stefano Signorini, Fabrizio Cappellini, Gabriele Riccardi, Massimo Boemi, Federica D’Angelo, R. Giansanti, Laura Tanase, Luigi Lanari, I Testa, Lucia Ricci, Francesca Pancani, A. Ranchelli, Paolo Vagheggi, Alessia Scatona, Lucia Fontana, Francesco Giorgino, Luigi Laviola, Lucia Tarantino, Claudia Ippolito, Vittoria Gigantelli, Mariangela Manicone, Eleonora Conte, Roberto Trevisan, Cristiana Scaranna, Rossella Rota, A. Corsi, Alessandro Roberto Dodesini, Giulio Marchesini Reggiani, Luca Montesi, Natalia Mazzella, Gabriele Forlani, Chiara Caselli, Raffaella Di Luzio, Arianna Mazzotti, Antimo Aiello, Angelina Barrea, Antonio Musto
Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci